Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company specializing in exosome-based therapies, has filed a provisional patent (#63/877,517) for a novel method of loading extracellular vesicles (EVs) with therapeutic compounds. The technology represents a significant advancement in drug delivery systems and positions the company to compete across multiple billion-dollar markets.
Patent Technology and Market Potential
The provisional patent covers a groundbreaking process for encapsulating active compounds into exosomes, naturally-secreted vesicles that can deliver therapeutic agents. According to the company, this method is designed to enhance loading efficiency and improve the stability and delivery of therapeutic agents.
The technology has applications across three major markets with substantial commercial potential:
- Pharmaceuticals: $1.77 trillion market size in 2025
- Nutraceuticals: Over $500 billion market value in 2025
- Cosmetics: Over $450 billion market value in 2025
"The filing of this provisional patent marks a pivotal moment for Exousia Pro, as it represents one of two new patent-ready technologies we have in development," said Matt Dwyer, President of Exousia Pro. "This proprietary technology is a critical asset that will provide us with a powerful market edge."
Commercial Strategy and Product Development
The patented loading technology will be utilized under the company's Exousia Health division. Dwyer indicated that the company is actively preparing to file for trademarks on several new products that will leverage this loading method, potentially expanding revenue opportunities.
The company's existing patented manufacturing process utilizes plant-based materials to create exosomes for commercial applications spanning dermatology to dentistry. The proprietary loading technology can infuse a range of molecules from drugs to DNA.
Funding and Clinical Development Plans
Concurrent with the patent filing, Exousia Pro has filed a Reg A offering (File #024-12629) to raise capital for advancing its clinical programs. The offering structure allows for raising between $1.235 million and $4.985 million depending on the percentage of shares sold.
The company plans to allocate the majority of funds toward Investigational New Drug (IND) trials, with specific focus on glioblastoma studies. At maximum funding levels, $2 million would be directed toward IND trials, while additional funds would support new product development ($1 million), potential acquisitions ($1.5 million), and laboratory equipment upgrades ($250,000).
"Exousia Pro can grow with funding; we can expand our studies, which could lead to further IND trials, but we do not have to do all these things at once and dilute the hell out of the Company's shareholders," Dwyer stated. The company intends to raise funds as needed according to an established schedule, maintaining the offering price without discounts.
Scientific Advisory Board and Partnership Strategy
The company's Scientific Advisory Board has identified the first new product planned for market introduction from mushroom exosomes. Exousia Pro is simultaneously working on partnering with large pharmaceutical companies while advancing its internal development programs.
The company operates with a lean structure and projects sales beginning this month, which influenced the allocation of minimal funds toward working capital in the funding plan.
